More recently, inhibitors of the Na+–glucose transport protein 2 (SGLT2) were added to the treatment regimen of heart failure patients, as it was shown to improve cardiovascular morbidity and mortality [28]. The gene discussed is SLC5A2; the disease is heart failure.